Skip NavigationSkip to Content
Return Return to Search Results

Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients

  1. Author:
    Shebzukhov, Y. V.
    Koroleva, E. P.
    Khlgatian, S. V.
    Belousov, P. V.
    Kuz'mina, K. E.
    Radko, B. V.
    Longpre, F.
    Lagarkova, M. A.
    Kadachigova, T. S.
    Gurova, O. V.
    Meshcheryakov, A. A.
    Lichinitser, M. R.
    Knuth, A.
    Jager, E.
    Kuprash, D. V.
    Nedospasov, S. A.

  2. Author Address

    Russian Acad Sci, Engelhardt Inst Mol Biol, Lab Mol Immunol, Moscow 119991, Russia. NCI, Basic Res Program, SAIC Frederick, Canc Res Ctr, Frederick, MD 21701 USA. NCI, Mol Immunoregulat Lab, Canc Res Ctr, Frederick, MD 21701 USA. Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Dept Mol Immunol, Moscow, Russia. Municipal Hosp 24, Dept Coloproctol 1, Moscow, Russia. Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia. Univ Zurich Hosp, Dept Oncol, CH-8091 Zurich, Switzerland. Krankenhaus NW Frankfurt, Med Klin 2, Frankfurt, Germany Nedospasov, SA, Russian Acad Sci, Engelhardt Inst Mol Biol, Lab Mol Immunol, Vavilov St 32, Moscow 119991, Russia
    1. Year: 2005
    2. Date: DEC 10
  2. Journal: International Journal of Cancer
    1. 117
    2. 5
    3. Pages: 800-806
  4. Type of Article: Article
  1. Abstract:

    Antibodies to cancer antigens can often be detected in the sera of patients, although the mechanism of the underlying Immoral immune response is poorly understood. Using immunoscreening of tumor-derived cDNA expression libraries (SEREX), we identified human histone deacetylase 3 (HDAC3) as serologically defined antigen in colon cancer. Closely related HDAC1 and HDAC2 do not elicit Immoral response in colon cancer patients. We show that the C-terminal region of HDAC3 protein lacking the homology to other Class I HDAC contains at least 3 distinct B-cell epitopes that are recognized by the serum antibodies. HDAC3 in combination with other SEREX antigens may become a useful molecular biomarker with diagnostic or prognostic value for a subset of colon cancer patients. (Supplementary material for this article can be found on the International Journal of Cancer website at http://www. interscience.wiley.com/jpages/0020-7136/suppmat/index.html). (c) 2005 Wiley-Liss, Inc

    See More

  1. Keywords:

External Sources

  1. View record in Web of Science®
  2. WOS: 000233031200014

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel